ABILITYPHARMAAbility Pharmaceuticals is a clinical stage drug discovery and development biopharmaceutical company
PIPELINEABTL0812, first-in-class, is currently in phase 2 clinical trials in lung cancer and endometrial cancer patients in Spain and France
SCIENCEAbilityPharma investigates cancer drugs inducing autophagy through the overexpression of TRIB3 and the inhibiton of the PI3K/Akt/mTOR pathway
ONGOING PHASE 2 CLINICAL TRIAL AS FIRST-LINE THERAPY IN PATIENTS WITH ADVANCED/METASTATIC ENDOMETRIAL CANCER OR LUNG CANCER - NOW RECRUITING PATIENTS AT VALL D'HEBRON INSTITUTE OF ONCOLOGY VHIO (BARCELONA), INSTITUT CATALÀ D'ONCOLOGIA (L’HOSPITALET, BADALONA AND GIRONA) AND INCLIVA (VALENCIA) - RECRUITING PATIENTS IN PARIS, MARSEILLE AND LYON IN SPRING 2017
AbilityPharma is a biopharmaceutical company focused on creating the future of oncology by developing innovative therapies that address unmet medical needs. Established in 2009 and with one product, ABTL0812, an oral autophagy targeted therapy in phase 2 clinical trials in patients with endometrial cancer and in squamous NSCLC, is positioning itself as one of the fast growers in the Catalan and Spanish biotech sector.